IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1026-1050 out of 1375.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

Public Release: 17-Mar-2015
JAMA
The link between aspirin, NSAIDs and colon cancer prevention may hinge on genetic variations
The link between taking aspirin, non-steroidal anti-inflammatory drugs, or NSAIDS, and colorectal cancer prevention is well established, but the mechanisms behind the protective effect have not been understood. A new study, co-led by investigators at Fred Hutchinson Cancer Research Center and published March 17 in JAMA, suggests this protection differs according to variations in DNA.
NIH/National Cancer Institute, National Institutes of Health, US Department of Health and Human Services

Contact: Kristen Woodward
kwoodwar@fredhutch.org
206-667-5095
Fred Hutchinson Cancer Research Center

Public Release: 17-Mar-2015
JAMA
Study examines diagnostic accuracy of pathologists interpreting breast biopsies
In a study in which pathologists provided diagnostic interpretation of breast biopsy slides, overall agreement between the individual pathologists' interpretations and that of an expert consensus panel was 75 percent, with the highest level of concordance for invasive breast cancer and lower levels of concordance for ductal carcinoma in situ and atypical hyperplasia, according to a study in the March 17 issue of JAMA.

Contact: Susan Gregg
sghanson@uw.edu
The JAMA Network Journals

Public Release: 17-Mar-2015
JAMA
Genetic background determines whether aspirin/NSAIDS will reduce colorectal cancer risk
An analysis of genetic and lifestyle data from 10 large epidemiologic studies confirmed that regular use of aspirin or NSAIDs appears to reduce the risk of colorectal cancer in most individuals but also found that a few individuals with rare genetic variants do not share this benefit.
NIH/National Cancer Institute, NIH/National Institute for Diabetes and Digestive and Kidney Diseases

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 17-Mar-2015
Nature Structural & Molecular Biology
3-D snapshot of protein highlights potential drug target for breast cancer
One of 15 different polymerases tasked with copying our genetic material, POLQ is singled out in this study for its unique role -- captured in an X-ray crystallography visual -- in DNA repair pathways linked to breast cancer, and therefore, potential as a drug target.
National Institutes of Health, Cancer Prevention and Research Institute of Texas, Grady F. Saunders, Ph.D., Distinguished Research Professorship, NIH/National Cancer Institute, NIH/National Institute of General Medical Sciences

Contact: Jennifer Nachbur
jennifer.nachbur@med.uvm.edu
802-656-7875
University of Vermont

Public Release: 17-Mar-2015
Lancet Oncology
Study suggests precision medicine for adrenal cancer
In a randomized phase 3 trial, adrenal cancer patients receiving the investigational drug linsitinib fared no better than patients receiving a placebo. But the researchers noticed a small subset of patients who had significant response and remained on the drug for an extended time.
Astellas

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 17-Mar-2015
JAMA
Effect of aspirin, NSAIDs on colorectal cancer risk may differ from genetic variations
Among approximately 19,000 individuals, the use of aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an overall lower risk of colorectal cancer, although this association differed according to certain genetic variations, according to a study in the March 17 issue of JAMA.

Contact: Katie Marquedant
KMARQUEDANT@PARTNERS.ORG
The JAMA Network Journals

Public Release: 17-Mar-2015
JAMA
Genetic markers play role in who benefits from aspirin, NSAIDs to lower colon cancer risk
An Indiana University cancer researcher and her colleagues have identified genetic markers that may help determine who benefits from regular use of aspirin and other nonsteroidal anti-inflammatory drugs for lowering one's risk of developing colorectal cancer.
National Institutes of Health

Contact: Michael Schug
maschug@iupui.edu
317-278-0953
Indiana University

Public Release: 17-Mar-2015
International Journal of Cancer
Microenvironment provides growth factor for metastasis
When a person has cancer that spreads to the bone and bone marrow, the tissue becomes increasingly fragile, often leading to increased bone resorption. In a surprising discovery, investigators at Children's Hospital Los Angeles found that when neuroblastoma cells metastasize to the bone, there initially occurs an increase in bone deposition, not resorption. They also determined that this process is driven by a chemical messenger called VEGFA.
National Institutes of Health, Ruth L. Kirschstein National Research Service Award

Contact: Ellin Kavanagh
ekavanagh@chla.usc.edu
323-361-7628
Children's Hospital Los Angeles

Public Release: 17-Mar-2015
Clinical Cancer Research
Macrophages may play critical role in melanoma resistance to BRAF inhibitors
Researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
National Institutes of Health, Commonwealth Universal Research Enhancement Program of the Pennsylvania Department of Health, The Wistar Institute Intramural Grants

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 17-Mar-2015
Journal of Economic Perspectives
Study: Prices of cancer drugs have soared since 1995
The prices of leading cancer drugs have risen at rates far outstripping inflation over the last two decades, according to a new study co-authored by an MIT economist -- but the exact reasons for the cost increases are unclear.
NIH/National Cancer Institute

Contact: Abby Abazorius
abbya@mit.edu
617-253-2709
Massachusetts Institute of Technology

Public Release: 16-Mar-2015
Nature Communications
Penn vet team points to new colon cancer culprit
Colon cancer is a heavily studied disease -- and for good reason. It is one of the leading causes of cancer-related deaths worldwide, and its numbers are on the rise, from 500,000 deaths in 1990 to 700,000 in 2010. This growth comes despite scientists' ever-increasing knowledge of the genetic mutations that initiate and drive this disease. Now, a team of researchers from the University of Pennsylvania has found evidence of a new culprit in the disease, a protein called MSI2.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Cancer Institute

Contact: Katherine Unger Baillie
kbaillie@upenn.edu
215-898-9194
University of Pennsylvania

Public Release: 16-Mar-2015
EMBO Journal
MDC cancer researchers identify new function in an old acquaintance
Cells have two different programs to safeguard them from developing cancer. One of them is senescence. It puts cancer cells into a permanent sleep. Now researchers of the Max Delbrück Center have discovered that an enzyme known to be active in breast cancer blocks this protection program and boosts tumor growth. They succeeded in blocking this enzyme in mice with breast cancer, thus reactivating senescence and stopping tumor growth.
German Cancer Society/Deutsche Krebshillfe

Contact: Barbara Bachtler
bachtler@mdc-berlin.de
49-309-406-3896
Max Delbrück Center for Molecular Medicine in the Helmholtz Association

Public Release: 16-Mar-2015
Journal of Proteome Research
Omics methods: Towards a better prediction of the effects of substances at very low doses
It was possible to demonstrate, for example, that even low quantities of benzopyrene can have effects on the protein pattern and hence the metabolism and signal pathways in cells, even though the concentration is a hundred times below what is required to drive cells directly into apoptosis. This is the conclusion of studies undertaken by the Helmholtz Centre for Environmental Research, Dresden University of Technology, and the German Federal Institute for Risk Assessment.
Helmholtz Association

Contact: Tilo Arnhold
presse@ufz.de
49-341-235-1635
Helmholtz Centre for Environmental Research - UFZ

Public Release: 16-Mar-2015
PLOS Computational Biology
New possibilities for the treatment of breast cancer arise, with the help of mathematics
Researchers of three of Switzerland's leading scientific institutions have brought to light a means of reprogramming a flawed immune response into an efficient anti-tumoral one by the results of a translational trial relating to breast cancer. Thanks to the innovative combination of mathematical modelization and experimentation, only 20 tests were necessary, whereas traditional experimentation would have required 596 tests to obtain the same results.

Contact: Ioannis Xenarios
Ioannis.Xenarios@isb-sib.ch
41-216-924-031
Swiss Institute of Bioinformatics

Public Release: 16-Mar-2015
Proceedings of the National Academy of Sciences
Spherical nucleic acids set stage for new paradigm in drug development
A Northwestern University-led research team led is the first to show spherical nucleic acids (SNAs) can be used as potent drugs to effectively train the immune system to fight disease, by either boosting or dampening the immune response. By increasing the immune response toward a specific cell type, SNAs could be used to target anything from influenza to different forms of cancer. If used to suppress the immune response, SNAs could target autoimmune disorders, such as rheumatoid arthritis and psoriasis.
National Institutes of Health, Center for Cancer Nanotechnology Excellence, Defense Advanced Research Projects Agency

Contact: Megan Fellman
fellman@northwestern.edu
847-491-3115
Northwestern University

Public Release: 16-Mar-2015
Cell
Dialing a bespoke signal
Exploring the fundamental mechanism by which a cell-surface receptor transmits its signal, an international team of Ludwig researchers and their colleagues has established proof of concept for an entirely new approach to drug design. They report that a class of synthetic molecules known as diabodies can, from outside the cell, latch onto a target receptor and manipulate it in such a manner as to induce distinct and varying effects within cells and tissues.
Ludwig Cancer Research, Howard Hughes Medical Institute, Belgian Federal Science Policy Office, de Duve Institute at the Université catholique de Louvain, Fondation contre le Cancer in Belgium

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research

Public Release: 16-Mar-2015
Obese women 40 percent more likely to get cancer
Obese women have around a 40 percent greater risk of developing a weight-related cancer in their lifetime than women of a healthy weight.

Contact: Emily Head
emily.head@cancer.org.uk
44-203-469-6189
Cancer Research UK

Public Release: 16-Mar-2015
Nature Reviews Immunology
Investigators find window of vulnerability for STIs to infect female reproductive tract
Dartmouth researchers have presented a comprehensive review of the role of sex hormones in the geography of the female reproductive tract and evidence supporting a 'window of vulnerability' to HIV and other sexually transmitted infections.
National Institutes of Health

Contact: Kirk Cassels
Kirk.A.Cassels@Hitchcock.org
603-653-6177
The Geisel School of Medicine at Dartmouth

Public Release: 16-Mar-2015
MD Anderson study, new hepatitis C drugs will place strain on health care system
The cost of treating people infected with the hepatitis C virus (HCV) with newly approved therapies will likely place a tremendous economic burden on the country's health care system. The prediction comes from a cost-effectiveness analysis led by researchers at the University of Texas MD Anderson Cancer Center.

Contact: Katrina Burton
kburton@mdanderson.org
713-792-8034
University of Texas M. D. Anderson Cancer Center

Public Release: 16-Mar-2015
Nature Plants
University of Sydney: Discovery holds promise for gene therapy and agriculture
A key step in understanding the genetic mechanism of plants' environmental adaptability has made in research led by the University of Sydney.

Contact: Verity Leatherdale
verity.leatherdale@sydney.edu.au
61-403-067-342
University of Sydney

Public Release: 16-Mar-2015
PLOS ONE
Predicting prostate cancer
A Northwestern University-led study in the emerging field of nanocytology could one day help men make better decisions about whether or not to undergo aggressive prostate cancer treatments.
National Institutes of Health, John and Carol Walter Center for Urological Health

Contact: Erin Spain
Spain@northwestern.edu
847-491-4888
Northwestern University

Public Release: 16-Mar-2015
Cell
Scientists find DNA is packaged like a yoyo
A research team led by University of Illinois professor of physics Taekjip Ha has found that DNA uncoils from the nucleosome asymmetrically (uncoiling from one end much more easily) in a recent publication in Cell.
National Science Foundation, National Institutes of Health, Howard Hughes Medical Institute

Contact: Nicholas Vasi
nvasi@illinois.edu
Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign

Public Release: 16-Mar-2015
Cancer Research
Study identifies 'lethal' subtype of prostate cancer
A University of Colorado Cancer Center study published in the journal Cancer Research defines a new, distinct subtype of 'lethal' prostate cancer marked by the loss of two genes, MAP3K7 and CHD1. Overall about 10 percent of men with prostate cancer will die from the disease. The study shows that of prostate cancer patients with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent prostate cancer, which ultimately leads to death. About 10 percent of all prostate cancers harbor combined MAP3K7-CHD1 deletions.
National Institutes of Health

Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Anschutz Medical Campus

Public Release: 16-Mar-2015
Journal of Cell Biology
Scripps Florida scientists confirm key targets of new anti-cancer drug candidates
In a new study, scientists from the Florida campus of the Scripps Research Institute have confirmed the ribosome assembly process as a potentially fertile new target for anti-cancer drugs by detailing the essential function of a key component in the assembly process.
National Institutes of Health, National Science Foundation, ThinkPink Kids Foundation, PGA National Women's Cancer Awareness Days, Swiss National Foundation

Contact: Eric Sauter
esauter@scripps.edu
267-337-3859
Scripps Research Institute

Public Release: 16-Mar-2015
Medical Care
Research calls for new policies to support women veterans' health care needs
As more women veterans seek health care in the Veterans Administration (VA) system, effective approaches are needed to ensure that their unique needs are recognized and met. A special April supplement to Medical Care collects new studies from an ongoing research initiative to inform health care policy for women veterans. The journal is published by Wolters Kluwer.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Showing releases 1026-1050 out of 1375.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

  Search News Releases

     

 

EurekAlert!